Rapidly Growing Harmony Biosciences Sees 30% Increase in Net Revenue, Boosts Growth Strategy With Rare Epilepsy Franchise Acquisition

Harmony Biosciences Holdings

PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has released their Q1 2024 report indicating a 30% year-over-year growth in net revenue, sealing the quarter ending March 31, 2024, on a promising note. The CNS-focused biotechnology firm has aggressively ramped up its growth strategy, expanding its innovative pipeline by adding a rare epilepsy franchise.

Harmony’s leadership believes the company is on a strong trajectory to get ahead in the competitive CNS biotech industry. This view is backed by Harmony’s transformation of its business operations through strategic alignments such as steady introduction of WAKIX, a narcolepsy medication, and a diversification of its portfolio through prudent business development.

Dr. Jeffrey M. Dayno, Harmony’s President and CEO, expressed his confidence in the company’s growth strategy, highlighting its potential in advancing the treatment of CNS disorders. Forecasted peak sales for its late-stage CNS assets are likely to hover between $1B to $2B.

Harmony anticipates launching a new product or indication at least annually over the next five years, with potential revenue reaching into billions beyond 2040. Encouragingly, sales of WAKIX are poised to surpass $1 billion in the adult narcolepsy market alone.

Harmony’s Key Franchise Highlights

Harmony has made impressive strides in extending and bolstering its CNS assets. Among its flagship brands, WAKIX net revenue amounts to $154.6 million in Q1 2024, representing an impressive growth of 30% compared to the same period last year.

Moreover, Harmony is on track to diversify WAKIX’s use with the progression of the IH program aimed at treating Idiopathic Hypersomnia. Additionally, in a move designed to protect its patent and establish longevity in the market, Harmony filed a provisional patent that could potentially extend protection for its Next-Gen pitolisant-based formulation up to 2044.

READ:  Optinose Reports Growth in Q1 and Optimistic Outlook for XHANCE

The company’s neurobehavioral portfolio equally holds promise, with the Phase 3 pivotal RECONNECT trial for Fragile X syndrome expected to be completed in early 2025.

Harmony Dives Into Rare Epilepsy Treatment

Marking a significant milestone, Harmony has acquired Epygenix Therapeutics, Inc., establishing a rare epilepsy franchise. This strategic acquisition is in line with Harmony’s commitment to developing cutting-edge treatments and medicines for patients with medical needs that are currently unmet. Harmony’s lead product, clemizole hydrochloride (EPX-100), will be pivotal in treating Dravet syndrome, with topline data expected in 2026.

Harmony’s Financial Highlights Q1 2024

Besides its medical advancements, Harmony’s financial results for the first quarter of 2024 are equally promising. The company’s net product revenue for Q1 2024 was $154.6 million, a significant increase of 30% compared to Q1 2023. This growth is mainly due to the strong commercial sales of WAKIX and expanding market penetration in the narcolepsy sector.

Moreover, Harmony reported a GAAP net income of $38.3 million or $0.67 per diluted share, marking a significant rise from the first quarter of 2023. The non-GAAP adjusted net income also rose to $50.7 million or $0.88 per diluted share for the first quarter of 2024, up from $40.1 million or $0.66 per diluted share for the same period in 2023.

In terms of operating expenses, Harmony reported an overall 30% increase in total operating expenses, which comes as a result of increased investing in research and development, sales and marketing, and general administrative costs.

Moreover, Harmony has reiterated its full-year 2024 net product revenue guidance, which it expects to be between $700 million and $720 million. As of March 31, 2024, Harmony’s cash and cash equivalents stood at $453.6 million, up from $425.6 million from December 31, 2023.

READ:  AdaptHealth Executives to Speak at 2024 BofA Securities Health Care Conference

In a move to boost shareholders’ value, Harmony’s Board of Directors has also left open the option for repurchasing common stock of up to $150 million as of March 31, 2024.

With these substantial strides forward, Harmony Biosciences has made it clear that it is a growing power in the CNS-focused biotechnology industry, building medical solutions to meet unmet needs and generating impressive financial returns in the process.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.